基于β-Cyclodextrin的纳米组件用于治疗动脉样硬化
Weihong Ji1,2, Yuanxing Zhang3, Weichen Shao1,2
1Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, PR China.
Regenerative biomaterials
|July 5, 2024
概括
贝塔-环氧德克斯 (β-CD) 纳米组件通过有效地输送药物,显示出治疗动脉样硬化的前景. 这些新型疗法提供了通过降低胆固醇和炎症来管理心血管疾病的新策略.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样硬化是心血管疾病的主要原因,需要改进治疗策略.
- 目前对动脉样硬化的治疗有局限性,这推动了对新型药物输送系统的搜索.
研究的目的:
- 审查基于β-cyclodextrin (β-CD) 的纳米组件作为动脉样硬化治疗方法的潜力.
- 突出各种β-CD纳米组装配方及其改善药物输送和疗效的机制.
主要方法:
- 专注于三类β-CD纳米组件:β-CD衍生物,β-CD/聚合物合物和聚合物β-CDs.
- 讨论了用于增强药物输送的配方策略和组装方法.
- 审查了β-CD纳米组件应用中的治疗机制和挑战.
主要成果:
- β-CD纳米组件可以降低胆固醇,减轻炎症,并可溶化疏水药物.
- 这些纳米组件有助于向血管组织提供向药物.
- 基于β-CD的各种纳米组件显示出改善动脉样硬化治疗结果的潜力.
结论:
- 基于β-CD的纳米组件代表了对动脉样硬化管理的有前途的新型治疗策略.
- 这些系统提供了系统的方法来克服心血管疾病中的药物输送障碍.
- 进一步开发和应用β-CD纳米组件为治疗动脉样硬化提供了显著的机会.
相关概念视频
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...